No green light for libido-boosting drug for women: US FDA
Friday 18 June 2010
The pink pill German drug firm Boehringer Ingelheim is trying to market in the United States as a libido-booster for women produced inconclusive results in two clinical trials, the Food and Drug Administration (FDA) said Wednesday.
Originally intended as an anti-depressant, the drug flibanserin - in the form of a pink pill - began being tested years ago as a potential libido aid after women said it failed to fight the blues but did boost their sex drive.
Lack of desire is the most common sexual problem in women aged 30 to 60, just as erectile dysfunction is the most common sexual disorder among men in the same age bracket, researchers said.
Clinical trials to test flibanserin's efficacy in raising the level of sexual desire in women were held in Canada, Europe and the United States.
The results of two US trials with the drug and a placebo were published on the FDA's website: "both failed to demonstrate a statistically significant improvement on the co-primary endpoint of sexual desire," said the FDA.
"Therefore, neither study met the agreed-upon criteria for success in establishing the efficacy of flibanserin for the treatment of HSDD (hypoactive sexual desire disorder)," the administration added.
Besides the inconclusive results, the FDA noted the drug in some patients caused side effects including depression and dizzyness.
The FDA said its is waiting for recommendations on the little pink pill from an independent panel of experts due to report on Friday. The administration is not legally bound to comply with the advice, but usually does.
Boehringer Ingelhein has been researching flibanserin as a treatment for post-menopausal HSDD in women since the popular Viagra hit the market for male ED in 1998.
The potential market for a libido booster for women has been estimated by some analysts at around two billion dollars.
Medical research has found that 40 percent of women suffer from different degrees of HSDD.
Flibanserin belongs to a family of anti-depressants that acts on the body's level of serotonin, a molecule that plays a role in mood changes.
sportLiverpool 5 Norwich City 1: Uruguayan striker has now scored 11 league goals against the club
arts + entsOlivier-nominated actor and singer is set to star in Lloyd Webber's musical about the Profumo affair
filmWith more than 70 per cent of early films lost, archivists are scouring the world to preserve the precious examples that remain
sportThe coach of Chalfont St Peter's under-10s football team was relieved of his duties after he sent an email to parents that said: 'I am only interested in winning'
techA piece of new hi-tech kit aims to get us scribbling again
indybestMake getting out of the wrong side of bed on cold winter mornings a thing of the past with our selection of night-time covers
life + styleClarissa Baldwin is the brains behind the slogan 'A Dog is for Life not just for Christmas'
Life & Style blogs
- 1 The hardwired difference between male and female brains could explain why men are 'better at map reading'
- 2 Is this the scariest advert ever? Japanese tyre commercial comes with its own disclaimer and health warning
- 3 UK chef creates world's most expensive ready meal - a fish pie costing £314
- 4 Food poverty in UK has reached level of 'public health emergency', warn experts
- 5 I’m sure Kate Moss doesn't care about posing for Playboy. But I do
£50000 - £70000 per annum + London: Harrington Starr: Senior Automation QA Eng...
£35000 - £50000 per annum + Benefits : Harrington Starr: SQL 2008 R2/2012 Deve...
£38000 - £45000 per annum + Benefits: Pro-Recruitment Group: Creative Audit Se...
£45000 - £50000 per annum + Benefits: Harrington Starr: SQL Developer (TSQL, P...